Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
Combination therapy with pegylated interferon-alpha plus ribavirin has greatly improved the
treatment efficacy and is the mainstream of treatment for chronic hepatitis C infection. The
efficacy and safety of pegylated interferon-alpha plus ribavirin combination therapy and its
impact on the outcome in older patients with chronic hepatitis C deserve to be elucidated.
The purposes of this study are:
1. To evaluate the efficacy of pegylated interferon-alpha 2a plus ribavirin combination
therapy in older patients with chronic hepatitis C
2. To investigate the safety of pegylated interferon-alpha 2a plus ribavirin combination
therapy in older patients with chronic hepatitis C
Phase:
Phase 4
Details
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital